Cephalon's full-year 2005 loss deepens 130%
Cephalon says that its 2005 loss worsened 130% year-on-year to $175.0 million, or $3.01 a share, due to the write-off of R&D expenses from its acquisition of Salmedix (Marketletter June 20, 2005) and Zeneus Pharma, as well as licensing rights to several drugs.
The US drugmaker saw 76% decline in fourth-quarter 2005 earnings, which reached $18.1 million, or $0.30 per share, failing to match estimates from industry observer. Analysts polled by Thomson Financial had predicted average earnings of $0.74 on revenue of $330.0 million for the three months ending December 2005.
Provigil key performance driver
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze